The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...
Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...
The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers in a ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The "Focal Segmental Glomerulosclerosis - Market Insight, Epidemiology, Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth assessment of FSGS ...
For 2Q26, Nomura Smid Cap Core Fund Institutional Class shares performed in-line with the Fund's benchmark, the Russell 2500 ...
Janus Henderson's Global Life Sciences portfolio returned 12.10% in Q2 2026, outperforming its benchmark. Read the full ...
Hosted on MSN
IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'
Travere TherapeuticsTVTX is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are flirting with a fresh buy point on the heels of a recent breakout. The San Diego-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results